PI Industries Limited — Investor Meet, 26-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

PI Industries posted ~6% standalone revenue growth and 17% EBITDA rise in FY25, with consolidated revenue up 4%. Agchem exports grew 5%, driven by 31% growth from new products launched in three years, making up 15%-18% of export sales. Domestic branded business rose 6% in revenue (9% volume growth), biologicals gained 20%, and pharma revenue surged 75% but remains EBITDA negative, with breakeven expected post-FY26. Management aims for mid-single-digit revenue growth in FY26, with strong export momentum in H2. CAPEX is planned at Rs. 800-900 Cr, focusing on CSM exports and pharma expansion. Net cash stands firm at Rs. 409 Cr.